middle.news
OncoSil Advances to Final FDA Review for Rare Cancer Device
9:48am on Tuesday 9th of June, 2026 AEST
•
Healthcare
Read Story
OncoSil Advances to Final FDA Review for Rare Cancer Device
9:48am on Tuesday 9th of June, 2026 AEST
Key Points
FDA moves OncoSil’s HDE application to final review
TRIPP-FFX trial meets co-primary endpoints with encouraging survival
OncoSil targets rare distal cholangiocarcinoma and unresectable pancreatic cancer
Potential US market entry within months pending final submissions
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Oncosil Medical (ASX:OSL)
OPEN ARTICLE